Inhibition of rotavirus infection in vitro and in vivo by a synthetic peptide from VP4

• Published in: Vaccine 1998-05, Vol.16 (9), p.916-920
• Main Authors: Ijaz, M.K., Nur-E-Kamal, M.S.A., Dar, F.K., Uduman, S., Redmond, M.J., Attah-Poku, S.K., Dent, D., Babiuk, L.A.
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Animals; anti-viral agents; Binding Sites - genetics; Biological and medical sciences; Capsid - genetics; Capsid - immunology; Capsid Proteins; Cattle; Cell Line; Fundamental and applied biological sciences. Psychology; Mice; Microbiology; Molecular Sequence Data; Peptide Fragments - genetics; Peptide Fragments - immunology; Receptors, Virus - immunology; Rotavirus - genetics; Rotavirus - immunology; Rotavirus - pathogenicity; Rotavirus Infections - immunology; Rotavirus Infections - prevention & control; Rotavirus Infections - virology; rotavirus vaccine; Trypsin; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Vaccines, Synthetic - pharmacology; Viral Vaccines - pharmacology; Virology; VP4-peptide
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/S0264-410X(97)00298-3

A synthetic peptide corresponding to bovine rotavirus C486 (BRV) VP4 amino acid sequence 232–255 (VP4-peptide) was studied with the objective of defining the origin of the protective immune response reported previously by Ijaz et al. (J. Virol. 1991, 65, 3106–3113). Pretreatment of MA-104 cells with the VP4-peptide before infection with rotavirus prevented both the attachment of 35S-labelled virus and plaque formation in vitro. In vivo studies using a murine rotavirus model demonstrated that intragastric administration of VP4-peptide protected subjects from challenge with virulent rotavirus. These results clearly indicate the importance of this epitope in virus-cell interactions and their potential as a rotavirus vaccine candidate.